

# ANTICANCER RESEARCH

## International Journal of Cancer Research and Treatment

ISSN: 0250-7005

Volume 37, Number 1, January 2017

### Contents

#### Reviews

- Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review. A.H. NGUYEN, S.Q. DETTY, D.K. AGRAWAL (*Omaha, NE, USA*) ..... 1
- Parenchymal-sparing Hepatectomy as the New Doctrine in the Treatment of Liver-metastatic Colorectal Disease: Beyond Oncological Outcomes. D. MORIS, D. DIMITROULIS, S. VERNADAKIS, A. PAPALAMPROS, E. SPARTALIS, A. PETROU, T.M. PAWLIK, E. FELEKOURAS (*Cleveland; Columbus, OH, USA; Athens, Greece*) ..... 9
- Three Pathways of Colonic Carcinogenesis in Rats. C.A. RUBIO (*Stockholm, Sweden*) ..... 15
- Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. J. POLIVKA JR, J. POLIVKA, L. HOLUBEC, T. KUBIKOVA, V. PRIBAN, O. HES, K. PIVOVARCIKOVA, I. TRESKOVA (*Plzen, Czech Republic*) ..... 21
- Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer. C. DAMASKOS, S. VALSAMI, M. KONTOS, E. SPARTALIS, T. KALAMPOKAS, E. KALAMPOKAS, A. ATHANASIOU, D. MORIS, A. DASKALOPOULOU, S. DAVAKIS, G. TSOUROUFLIS, K. KONTZOGLU, D. PERREA, N. NIKITEAS, D. DIMITROULIS (*Athens, Greece; Aberdeen, UK; Cleveland, OH, USA*) ..... 35

#### Experimental Studies

- KIF11 Is Required for Spheroid Formation by Oesophageal and Colorectal Cancer Cells. T. IMAI, N. OUE, K. SENTANI, N. SAKAMOTO, N. URAOKA, H. EGI, T. HINOI, H. OHDAN, K. YOSHIDA, W. YASUI (*Hiroshima; Gifu; Kure, Japan*) ..... 47

Contents continued on the back cover

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment



ISSN (print): 0250-7005  
ISSN (online): 1791-7530

## Editorial Board

- P. A. ABRAHAMSSON**, Malmö, Sweden  
**B. B. AGGARWAL**, Houston, TX, USA  
**T. AKIMOTO**, Kashiwa, Chiba, Japan  
**P. Z. ANASTASIADIS**, Jacksonville, FL, USA  
**A. ARGIRIS**, San Antonio, TX, USA  
**J. P. ARMAND**, Toulouse, France  
**V. I. AVRAMIS**, Los Angeles, CA, USA  
**D.-T. BAU**, Taichung, Taiwan, ROC  
**G. BAUER**, Freiburg, Germany  
**E. E. BAULIEU**, Le Kremlin-Bicetre, France  
**E. J. BENZ, Jr.**, Boston, MA, USA  
**J. BERGH**, Stockholm, Sweden  
**F. T. BOSMAN**, Lausanne, Switzerland  
**M. BOUVET**, La Jolla, CA, USA  
**J. BOYD**, Miami, FL, USA  
**G. BROICH**, Monza, Italy  
**Ø. S. BRULAND**, Oslo, Norway  
**J. M. BUATTI**, Iowa City, IA, USA  
**M. M. BURGER**, Basel, Switzerland  
**M. CARBONE**, Honolulu, HI, USA  
**C. CARLBERG**, Kuopio, Finland  
**J. CARLSSON**, Uppsala, Sweden  
**A. F. CHAMBERS**, London, ON, Canada  
**P. CHANDRA**, Frankfurt am Main, Germany  
**L. CHENG**, Indianapolis, IN, USA  
**R.-G. CHUNG**, Taichung, Taiwan, ROC  
**J. CLARKE**, Washington, DC, USA  
**E. DE CLERCQ**, Leuven, Belgium  
**W. DEN OTTER**, Amsterdam, The Netherlands  
**E. P. DIAMANDIS**, Toronto, ON, Canada  
**G. TH. DIAMANDOPOULOS**, Boston, MA, USA  
**D. W. FELSHER**, Stanford, CA, USA  
**J. A. FERNANDEZ-POL**, Chesterfield, MO, USA  
**I. J. FIDLER**, Houston, TX, USA  
**A. P. FIELDS**, Jacksonville, FL, USA  
**H. FU**, Atlanta, GA, USA  
**B. FUCHS**, Zurich, Switzerland  
**D. FUCHS**, Innsbruck, Austria  
**G. GABBIANI**, Geneva, Switzerland  
**R. GANAPATHI**, Charlotte, NC, USA  
**A. F. GAZDAR**, Dallas, TX, USA  
**J. H. GESCHWIND**, Baltimore, MD, USA  
**A. GIORDANO**, Philadelphia, PA, USA  
**G. GITSCH**, Freiburg, Germany  
**R. H. GOLDFARB**, Guilford, CT, USA  
**L. HELSON**, Quakertown, PA, USA  
**R. HENRIKSSON**, Umeå, Sweden  
**R. M. HOFFMAN**, San Diego, CA, USA  
**S. C. JHANWAR**, New York, NY, USA  
**J. V. JOHANNESSEN**, Oslo, Norway  
**B. KAINA**, Mainz, Germany  
**P. -L. KELLOKUMPU-LEHTINEN**, Tampere, Finland  
**D. G. KIEBACK**, Schleswig, Germany  
**R. KLAPDOR**, Hamburg, Germany  
**S. D. KOTTARIDIS**, Athens, Greece  
**G. R. F. KRUEGER**, Köln, Germany
- Pat M. KUMAR**, Manchester, UK  
**Shant KUMAR**, Manchester, UK  
**O. D. LAERUM**, Bergen, Norway  
**F. J. LEJEUNE**, Lausanne, Switzerland  
**S. LINDER**, Linköping, Sweden  
**L. F. LIU**, Piscataway, NJ, USA  
**D. M. LOPEZ**, Miami, FL, USA  
**E. LUNDGREN**, Umeå, Sweden  
**Y. MAEHARA**, Fukuoka, Japan  
**J. MAHER**, London, UK  
**J. MARESCAUX**, Strasbourg, France  
**J. MARK**, Skövde, Sweden  
**S. S. MARTIN**, Baltimore, MD, USA  
**S. MITRA**, Houston, TX, USA  
**S. MIYAMOTO**, Fukuoka, Japan  
**S. MONCADA**, Manchester, UK  
**M. MUELLER**, Villingen-Schwenningen, Germany  
**F. M. MUGGIA**, New York, NY, USA  
**M. NAMIKI**, Kanazawa, Ishikawa, Japan  
**R. NARAYANAN**, Boca Raton, FL, USA  
**K. NILSSON**, Uppsala, Sweden  
**S. PATHAK**, Houston, TX, USA  
**J.L. PERSSON**, Malmö, Sweden  
**G. J. PILKINGTON**, Portsmouth, UK  
**C. D. PLATSOUCAS**, Norfolk, VA, USA  
**A. POLLIACK**, Jerusalem, Israel  
**M. RIGAUD**, Limoges, France  
**U. RINGBORG**, Stockholm, Sweden  
**M. ROSELLI**, Rome, Italy  
**S.T. ROSEN**, Duarte, CA, USA  
**A. SCHAUER**, Göttingen, Germany  
**M. SCHNEIDER**, Wuppertal, Germany  
**J. SEHOULLI**, Berlin, Germany  
**A. SETH**, Toronto, ON, Canada  
**G. V. SHERBET**, Newcastle-upon-Tyne, UK  
**A. SLOMINSKI**, Birmingham, AL, USA  
**G.-I. SOMA**, Kagawa, Japan  
**G. S. STEIN**, Burlington, VT, USA  
**T. STIGBRAND**, Umeå, Sweden  
**T. M. THEOPHANIDES**, Athens, Greece  
**P. M. UELAND**, Bergen, Norway  
**H. VAN VLIERBERGHE**, Ghent, Belgium  
**R. G. VILE**, Rochester, MN, USA  
**M. WELLER**, Zurich, Switzerland  
**J. WESTERMARCK**, Turku, Finland  
**B. WESTERMARCK**, Uppsala, Sweden  
**Y. YEN**, Duarte, CA, USA  
**M.R.I. YOUNG**, Charleston, SC, USA  
**B. ZUMOFF**, New York, NY, USA
- G. J. DELINASIOS**, Athens, Greece  
Managing Editor and  
Executive Publisher
- J. G. DELINASIOS**, Athens, Greece  
Managing Editor (1981-2016)

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

**U.S. Branch:** Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

E-mails: Editorial Office: journals@iia-anticancer.org

Managing Editor: editor@iia-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research. The IIAR is a member of UICC. For more information about ANTICANCER RESEARCH, IIAR and the Conferences, please visit the IIAR website: [www.iia-anticancer.org](http://www.iia-anticancer.org)

**Publication Data:** ANTICANCER RESEARCH (AR) is published bimonthly from January 1981 to December 2008 and monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

**Copyright:** On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

**Annual Subscription Rates 2017 per volume:** Institutional subscription US\$ 1,898.00 (online) or US\$ 2,277.00 (print & online). Personal subscription US\$ 897.00 (online) or US\$ 1,277.00 (print & online). Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-36, 1981-2016) are available at 50% discount on the above rates.

**Subscription Orders:** Orders can be placed at agencies, bookstores, or directly with the Publisher. (e-mail: [subscriptions@iia-anticancer.org](mailto:subscriptions@iia-anticancer.org))

**Advertising:** All correspondence and rate requests should be addressed to the Editorial Office.

**Book Reviews:** Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Obtaining permission to reuse or reproduce our content: AR has partnered with Copyright Clearance Center (CCC) to make it easy to secure permissions to reuse its content. Please visit [www.copyright.com](http://www.copyright.com) and enter the title that you are requesting permission for in the 'Get Permission' search box. For assistance in placing a permission request, Copyright Clearance Center can be contacted directly at: Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. Phone: +1-978-750-8400. Fax: +1-978-646-8600. E-mail: [info@copyright.com](mailto:info@copyright.com).

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios). All rights reserved.

D.T.P. BY IIAR

PRINTED BY ENTYP0, ATHENS, GREECE. PRINTED ON ACID-FREE PAPER

# ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment  
ISSN (print): 0250-7005, ISSN (online): 1791-7530

VOLUME 37  
2017

## Editorial Board

<b>P. A. Abrahamsson</b>	Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden
<b>B. B. Aggarwal</b>	Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
<b>T. Akimoto</b>	Division of Particle Therapy and Department of Radiation Oncology, National Cancer Center East, Kashiwa, Chiba, Japan
<b>P. Z. Anastasiadis</b>	Department of Cancer Biology, Mayo Cancer Center, Jacksonville, FL, USA
<b>A. Argiris</b>	Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA
<b>J. P. Armand</b>	Institut Claudius Regaud, Toulouse, France
<b>V. I. Avramis</b>	Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
<b>D.-T. Bau</b>	Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC
<b>G. Bauer</b>	Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany
<b>E. E. Baulieu</b>	INSERM U488 and College de France, Le Kremlin-Bicetre, France
<b>E. J. Benz, Jr.</b>	Dana-Farber Cancer Institute, Boston, MA, USA
<b>J. Bergh</b>	Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
<b>F. T. Bosman</b>	Institute of Pathology, University of Lausanne, Switzerland
<b>M. Bouvet</b>	Department of Surgery, University of California San Diego, Moores Cancer Center, La Jolla, CA, USA
<b>J. Boyd</b>	Department of Human and Molecular Genetics, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA
<b>G. Broich</b>	Gruppo Policlinico di Monza, Monza, Italy
<b>Ø. S. Bruland</b>	Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
<b>J. M. Buatti</b>	Department of Radiation Oncology, University of Iowa, Iowa City, IA, USA
<b>M. M. Burger</b>	Novartis, Basel, Switzerland
<b>M. Carbone</b>	Cancer Research Center of Hawaii, Honolulu, HI, USA
<b>C. Carlberg</b>	Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
<b>J. Carlsson</b>	Department of Biomedical Radiation Sciences, Uppsala University, Sweden
<b>A. F. Chambers</b>	Department of Oncology, London Regional Cancer Center, London, Ontario, Canada
<b>P. Chandra</b>	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
<b>L. Cheng</b>	Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
<b>J.-G. Chung</b>	Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC
<b>R. Clarke</b>	Georgetown University Medical Center, Washington, DC, USA
<b>E. De Clercq</b>	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
<b>W. Den Otter</b>	VUMC, Department of Urology, Amsterdam, The Netherlands
<b>E. P. Diamandis</b>	Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
<b>G. Th. Diamandopoulos</b>	Department of Pathology, Harvard Medical School, Boston, MA, USA
<b>D. W. Felsher</b>	Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
<b>J. A. Fernandez-Pol</b>	Metalloproteomics, LLC, Chesterfield, MO, USA
<b>I. J. Fidler</b>	Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
<b>A. P. Fields</b>	Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA
<b>H. Fu</b>	Discovery and Developmental Therapeutics Program of Winship Cancer Institute, Emory University, Atlanta, GA, USA
<b>B. Fuchs</b>	Balgrist University Hospital, Zurich, Switzerland
<b>D. Fuchs</b>	Center for Chemistry and Biomedicine, Innsbruck Medical University, Innsbruck, Austria
<b>G. Gabbiani</b>	Department of Pathology, University of Geneva, Switzerland

<b>R. Ganapathi</b>	Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
<b>A. F. Gazdar</b>	Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA
<b>J. H. Geschwind</b>	Interventional Radiology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
<b>A. Giordano</b>	Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
<b>G. Gitsch</b>	Department of Gynecology and Obstetrics, University of Freiburg, Germany
<b>R. H. Goldfarb</b>	R. H. Goldfarb Sopherion Therapeutics, LLC and Translational Oncology and ImmunoEngineering Consulting, Guilford, CT, USA
<b>L. Helson</b>	Sign Path Pharma, Inc., Quakertown, PA, USA
<b>R. Henriksson</b>	Department of Experimental Oncology, Umeå University, Umeå, Sweden
<b>R. M. Hoffman</b>	Department of Surgery, University of California, San Diego, CA, USA
<b>S. C. Jhanwar</b>	Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
<b>J. V. Johannessen</b>	Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
<b>B. Kaina</b>	Institute of Toxicology, University of Mainz, Germany
<b>P. -L. Kellokumpu-Lehtinen</b>	Department of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland
<b>D. G. Kieback</b>	Helios Medical Center Schleswig, Schleswig, Germany
<b>R. Klapdor</b>	Medical Clinic, University of Hamburg, Germany
<b>S. D. Kottaridis</b>	Department of Virology, Hellenic Anticancer Institute, Athens, Greece
<b>G. R. F. Krueger</b>	Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
<b>Pat M. Kumar</b>	Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK
<b>Shant Kumar</b>	Department Pathology, University of Manchester Medical School, Manchester, UK
<b>O. D. Laerum</b>	Department of Pathology, The Gade Institute, University of Bergen, Norway
<b>F. J. Lejeune</b>	Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
<b>S. Linder</b>	Department of Medicine and Health, Linköping University, Linköping, Sweden
<b>L. F. Liu</b>	Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA
<b>D. M. Lopez</b>	Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
<b>E. Lundgren</b>	Unit of Applied Cell and Molecular Biology, University of Umeå, Sweden
<b>Y. Maehara</b>	Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
<b>J. Maher</b>	Department of Research Oncology, Division of Cancer Studies, King's College London School of Medicine, Guy's Hospital Campus, London, UK
<b>J. Marescaux</b>	IRCAD, University of Strasbourg, France
<b>J. Mark</b>	Department of Pathology, Kärnshuset, Skövde, Sweden
<b>S. S. Martin</b>	Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, USA
<b>S. Mitra</b>	The Methodist Hospital Research Institute (TMHRI), Houston, TX, USA
<b>S. Miyamoto</b>	Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
<b>S. Moncada</b>	Manchester Cancer Research Centre, University of Manchester, Manchester, UK
<b>M. Mueller</b>	Hochschule Furtwangen University, Villingen-Schwenningen, Germany
<b>F. M. Muggia</b>	New York University Cancer Institute, School of Medicine, NY, USA
<b>M. Namiki</b>	Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa City, Ishikawa, Japan
<b>R. Narayanan</b>	Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
<b>K. Nilsson</b>	Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden
<b>S. Pathak</b>	Department of Cell Biology, University of Texas, Houston, TX, USA
<b>J. L. Persson</b>	Section for Experimental Cancer Research, Clinical Research Center, Lund University, Malmö, Sweden

- G. J. Pilkington** Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK
- C. D. Platsoucas** College of Sciences, Old Dominion University, Norfolk, VA, USA
- A. Polliack** Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
- M. Rigaud** Laboratory Biochimie et Génétique Molecules, Faculté de Médecine de Limoges, France
- U. Ringborg** Department of General Oncology, Karolinska Hospital, Stockholm, Sweden
- M. Roselli** Department of Medical Oncology, University of Rome "Tor Vergata", Italy
- S.T. Rosen** Comprehensive Cancer Center and Beckman Research Institute, Duarte, CA, USA
- A. Schauer** Zentrum Pathologie, Georg-August Universität, Göttingen, Germany
- M. Schneider** Department of Organic Chemistry, Bergische University, Wuppertal, Germany
- J. Sehoul** Department of Gynecology, Center for Oncological Surgery, Charité Comprehensive Cancer Center, Berlin, Germany
- A. Seth** Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada
- G. V. Sherbet** Cancer Research Unit, University of Newcastle-upon-Tyne, UK
- A. Slominski** Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA
- G.-I. Soma** Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, Kagawa, Japan
- G. S. Stein** Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA
- T. Stigbrand** Department of Immunology, Umeå University, Umeå, Sweden
- T. M. Theophanides** Department of Chemistry, Technical University of Athens, Greece
- P. M. Ueland** Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Norway
- H. Van Vlierberghe** Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
- R.G. Vile** Department of Immunology, Mayo Clinic, Rochester, MN, USA
- M. Weller** Department of Neurology, University Hospital Zurich, Zurich, Switzerland
- J. Westermark** Centre for Biotechnology, University of Turku, Turku, Finland
- B. Westermark** Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden
- Y. Yen** Department of Molecular Pharmacology, City of Hope, Duarte, CA, USA
- M. R. I. Young** Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA
- B. Zumoff** Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA

## Acknowledgements

The IAR appreciates the support of the following Foundations, Institutions, Organizations and Universities for the works published in Anticancer Research, Volume 36, 2016.

- A.P. Moeller Foundation, Copenhagen, Denmark  
 Academic Scholarship, Seoul National University College of Medicine Alumni Association, Port Washington, NY, U.S.A.
- Academy of Finland, Helsinki, Finland  
 Advanced Research Foundation Inc., New Rochelle, NY, U.S.A.
- Albert Hung Foundation, Hong Kong, P.R. China  
 Algeria's General Directorate for Scientific Research and Technological Development (DGRSDT), Algiers, Algeria  
 Alliance Pour la Recherche En Cancérologie (APREC), Paris, France  
 Alma Toorock Memorial for Cancer Research, Brooklyn, NY, U.S.A.  
 American Association of Cancer Researchers, Philadelphia, PA, U.S.A.  
 American Cancer Society, Atlanta, GA, U.S.A.  
 American Chemical Society (ACS), Washington, DC, U.S.A.  
 American Heart Association, Dallas, TX, U.S.A.  
 American Journal Experts (AJE), Durham, NC, U.S.A.  
 Asa Norte Regional Hospital (HRAN), Brasília, Brazil  
 Asahi Kasei Pharma Corp., Tokyo, Japan  
 Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea  
 Assistance Publique des Hôpitaux de Paris (APHP), Paris, France  
 Austrian Science Fund (FWF), Vienna, Austria  
 Avtal om Läkarutbildning och Forskning (ALF), Lund University and Region Skane, Lund, Sweden
- Basic Science Research Program, National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea  
 Bavarian State Ministry of the Environment and Consumer Protection, Munich, Germany  
 Bayer HealthCare Pharmaceuticals, Montville, NJ, U.S.A.  
 Becket-Fonden, Copenhagen, Denmark  
 Beijing Municipal Science & Technology Commission, Beijing, P.R. China  
 Benson Idahosa University, Benin City, Nigeria  
 Beppu Medical Center, Beppu, Japan  
 Berlin Institute of Health, Berlin, Germany  
 Bettina Bräu Foundation, Munich, Germany
- Bio and Medical Technology Department Program, National Research Foundation (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea  
 Biobanking and BioMolecular resources Research Infrastructure (BBMRI), Austria  
 Bio-oriented Technology Research Advancement Institution, National Agriculture and Food Research Organization (NARO), Tsubuka, Japan  
 Bioscience Group and Head, Radiation Biology & Health Sciences Division (BARC), Mumbai, India  
 Biozoom Services GmbH, Kassel, Germany  
 Bone and Soft-Tissue Clinic, Peter McCallum Cancer Institute, Melbourne, VIC, Australia  
 Bonner Forschung (BONFOR ) Research Grant, University Medical Center, University of Bonn, Bonn, Germany  
 Boston University School of Medicine (BUSM), Boston, MA, U.S.A.  
 Brain Tumour Foundation of Canada, London, ON, Canada  
 Breast Cancer Hope Foundation, London, U.K.  
 Breast Cancer Now, London, U.K.  
 Breast Cancer Research Foundation, New York, NY, U.S.A.
- California State University Dominguez Hills, Carson, CA, U.S.A.  
 Canadian Breast Cancer Foundation, Canada  
 Canadian Tumour Repository Network, Canada  
 Cancer and Allergy Foundation, Gothenburg, Sweden  
 Cancer Care West-Hardiman Scholarship, Galway, Ireland  
 Cancer Registry, Hannover Medical School, Hannover, Germany  
 Cancer Research Foundation Norrland, Umeå, Sweden  
 Cancer Research Society, Ottawa, ON, Canada  
 Cancer Research Wales, Wales, U.K.  
 Cancer Society, Stockholm, Sweden  
 Cancéropôle Grand Ouest, Lille, France  
 Capacity Development Award, Canadian Cancer Society, Canada  
 Cardiff China Medical Research Collaborative, Cardiff University, Wales, U.K.  
 Cardiff University's China Medical Scholarship, Cardiff University, Wales, U.K.  
 Catholic Medical Center Research Foundation, Seoul, Republic of Korea

- Center for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan
- Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan
- Center for Drug Design, Academic Health Center, University of Minnesota, Minneapolis, MN, U.S.A.
- Center for Neuroscience Research, Children's Research Institute, Children's National Medical Center, Washington, DC, U.S.A.
- Center of Innovation Program, Japan Science and Technology Agency (JST), Kawaguchi, Japan
- Center of Life Sciences, Hiroshima University, Higashihiroshima, Japan
- Centre National de la Recherche Scientifique (CNRS), Paris, France
- Chang Gung Memorial Hospital, Taipei, Taiwan, R.O.C.
- Charité Universitätsmedizin Berlin, Berlin, Germany
- Charles R. Drew University of Medicine and Science, Willowbrook, CA, U.S.A.
- China Medical University Hospital, Taichung, Taiwan, R.O.C.
- China Medical University, Taichung, Taiwan, R.O.C.
- China Natural Science Foundation, Guangdong, P.R. China
- China Scholarship Council, Beijing, P.R. China
- ChromoTek, Martinsried, Germany
- Chulalongkorn University, Bangkok, Thailand
- Chungnam National University, Daejeon, Republic of Korea
- Circulating Tumor Cells Therapeutic Apheresis (CTCTRAP), the Netherlands
- City of Hope, National Medical Center, Duarte, CA, U.S.A.
- Clariant Inc., Aliso Viejo, CA, U.S.A.
- Claudia von Schilling Foundation for Breast Cancer Research, Hannover, Germany
- Cleveland Clinic, Cleveland, OH, U.S.A.
- Clinical Research Institute, National Kyushu Cancer Center, Fukuoka, Japan
- Clinical Research Support (CRES) Center Kyushu, Fukuoka City, Japan
- Clinical Sciences Research and Development Program, Department of Veterans Affairs, Washington, DC, U.S.A.
- Clinical Trial and Research Center of Excellence, Ministry of Health and Welfare, Taipei, Taiwan, R.O.C.
- Cluster of Excellence Engineering of Advanced Materials (EAM), Erlangen, Germany
- Collaborative Innovation Center of Chinese Oolong Tea Industry, College of Tea and Food Science, Wuyi University, Wuyishan, P.R. China
- Commission on Cancer, American College of Surgeons, Chicago, IL, U.S.A.
- Compagnia di San Paolo, Turin, Italy
- Comprehensive Cancer Center, Wake Forest University Baptist Medical Center, Winston-Salem, NC, U.S.A.
- Comprehensive Support Project for Cooperative Clinical Research, Public Health Research Foundation, Tokyo, Japan
- Conceptual Development of Research Organization, Faculty Hospital in Pilsen (FNPI), Ministry of Health, Prague, Czech Republic
- Conseil Départemental de Haute Corse, Bastia, Corsica, France
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brasília, Brazil
- Cooperation in Science and Technology (COST), EU RTD Framework Program, Brussels, Belgium
- Cooperative Research Grant, Institute for Enzyme Research, Joint Usage/Research Center, University of Tokushima, Tokushima, Japan
- Cooperative Research Program, Network Joint Research Center for Materials and Devices, Osaka, Japan
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasília, Brazil
- Council for Science, Technology and Innovation (CSTI), Tokyo, Japan
- Council Of Scientific & Industrial Research (CSIR)- Central Food Technological Research Institute (CFTRI), Mysuru, India
- Council of Scientific & Industrial Research (CSIR) Scientific & Industrial Research (SRF), University Grants Commission (UGC), New Delhi, India
- Croatian Science Foundation, Zagreb, Croatia
- Cross-ministerial Strategic Innovation Promotion Program (SIP), Japan
- Danish Cancer Society, Copenhagen, Denmark
- Danish Center for Interventional Research in Radiation Oncology (CIRRO), The Lundbeck Foundation Centre for Interventional Research in Radiation Oncology, Aarhus, Denmark
- Danish Council for Strategic Research, Copenhagen, Denmark
- Danish Head and Neck Cancer Group (DAHANCA), Aarhus, Denmark
- Dansk Kraeftforsknings Fund, Copenhagen, Denmark
- Darren Manelski Foundation, U.S.A.
- Dartmouth Synergy Clinical and Translational Science Institute, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), Bethesda, MD, U.S.A.



- David Geffen School of Medicine at UCLA, Los Angeles, CA, U.S.A.
- Deanship of Scientific Research (DSR), King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
- Dell'Angelo Hospital Mestre-Venice, Venice, Italy
- Department of Clinical Research Center, Wakayama Medical University, Wakayama, Japan
- Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan
- Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, Second University of Naples, Caserta, Italy
- Department of Gastroenterological Surgery and Urology, Osaka University, Osaka, Japan
- Department of Gastroenterology and Hepatology, Osaka University, Osaka, Japan
- Department of Health, Biotechnology Research Program, Commonwealth of Pennsylvania, U.S.A.
- Department of Histology and Embryology, Wrocław Medical University, Wrocław, Poland
- Department of Integrative medicine, Osaka University, Osaka, Japan
- Department of International Medical Communications, Tokyo Medical University, Tokyo, Japan
- Department of Medical Sciences, The Graduate School, Ajou University, Suwon, Republic of Korea
- Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka City, Japan
- Department of Medicine, University of Wisconsin, Madison, WI, U.S.A.
- Department of Molecular Pharmacology and Oncology, Gunma University Graduate School of Medicine, Gunma, Japan
- Department of Nuclear Medicine, Taichung Tzu Chi Hospital, Taichung, Taiwan, R.O.C.
- Department of Obstetrics and Gynecology, University of Tübingen, Tübingen, Germany
- Department of Oncology, University Hospital of Ioannina, Ioannina, Greece
- Department of Ophthalmology, University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany
- Department of Oral Pathology, Institute of Pathology, Universitätsklinik Hamburg-Eppendorf, Hamburg, Germany
- Department of Orthopaedics, St. Vincent's Hospital Melbourne, Fitzroy, VIC, Australia
- Department of Pathology and Laboratory Medicine Service, Minneapolis VA Medical Center, Minneapolis, MN, U.S.A.
- Department of Pathology, Radiumhospitalet, Oslo University Hospital, Oslo, Norway
- Department of Radiation Oncology, Gunma University, Maebashi, Japan
- Department of Science and Technology, Guangxi Province, P.R. China
- Department of Veterans Affairs, Washington, DC, U.S.A.
- Departments of Surgical Pathology, Library, Medical Media and Research Services, Minneapolis VA Medical Center, Minneapolis, MN, U.S.A.
- Departments of Urology, Radiology and Radiation Oncology, Osaka Medical College, Takatsuki, Japan
- Dermal Toxicology and Effects Group, Centre for Radiation, Chemical and Environmental Hazards, Public Health England, U.K.
- Des Moines University, Des Moines, IA, U.S.A.
- Desna Robins Jones Charitable Trust, Bridgend, U.K.
- Deutsche Forschungsgemeinschaft (DFG), Bonn, Germany
- Deutsche Krebshilfe, Bonn, Germany
- DexTech Medical AB, Uppsala, Sweden
- Diversity Grant, National Institute of Radiological Sciences (NIRS)-Chiba University, Japan
- Division of Gastroenterology and Hepatology, University of Wisconsin, Madison, WI, U.S.A.
- Dynamic Science S.L., Barcelona, Spain
- Edanz, Fukuoka, Japan
- Editage, Tokyo, Japan
- Eisai GmbH, Frankfurt, Germany
- Eli Lilly and Company, Indianapolis, IN, U.S.A.
- Else og Mogens Wedell-Wedellsborgs Fond, Skodsborg, Denmark
- Enrico and Enrica Sovena Foundation, Italy
- European Institute of Oncology, Milan, Italy
- European Regional Development Fund (ERDF), Brussels, Belgium
- European Social Fund (ESF), European Commission, Brussels, Belgium
- European Structural and Investment Funds, European Commission, Brussels, Belgium
- EuroTransBio (ETB), Seventh Framework Programme, European Commission, Brussels, Belgium
- Experimental Pathology, University of Wisconsin Carbone Cancer Center, Madison, WI, U.S.A.
- Ez Communications, Matsumoto, Japan
- F. Hoffmann-La Roche AG, Basel, Switzerland
- Fabrikant Einer Willumsens Mindelegat, Copenhagen, Denmark

- Fabrikant Willumsens Mindelegat, Copenhagen, Denmark
- Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris Descartes, Paris, France
- Faculty Hospital in Pilsen (FNPI), Pilsen, Czech Republic
- Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic
- Faculty of Medicine Publication Clinic, Khon Kaen University, Khon Kaen, Thailand
- Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
- Fellowships of Excellence for Postgraduate Studies in Greece-Siemens Program, State Scholarships Foundation (IKY), Athens, Greece
- Finnish Anti-tuberculosis Association, Helsinki, Finland
- Finnish Cancer Society, Helsinki, Finland
- Finnish Dental Society Apollonia, Helsinki, Finland
- Finnish Medical Foundation, Helsinki, Finland
- Finnish Medical Society Duodecim, Helsinki, Finland
- Finnish Society For Oncology, Helsinki, Finland
- Flint Animal Cancer Center, Colorado State University, Fort Collins, CO, U.S.A.
- Fondation des Hôpitaux Enfant-Jésus – St-Sacrement (HEJ-SS), Ville de Québec, QC, Canada
- Fondation du Cancer du Sein du Québec, Ville de Québec, QC, Canada
- Fondation pour la Recherche Médicale (FRM), Paris, France
- Fondazione Comunità Bresciana Onlus, Brescia, Italy
- Fondazione Guido Berlucci per la Ricerca sul Cancro Onlus, Borgonato, Italy
- Fonds de recherche du Québec - Santé (FRQS), Montréal, QC, Canada
- Förderung für Forschung und Lehre, LMU University, Munich, Germany
- Forschungsförderung Ruhr-Universität Bochum Medizinischen Fakultät (FoRUM) Grant, Ruhr-University Bochum, Bochum, Germany
- Foundation for Polish Science, Warsaw, Poland
- Foundation for Promotion of Cancer Research, Tokyo, Japan
- Foundation of Beijing Educational Committee, Beijing, P.R. China
- Foundation of Skin Physiology, Donors' Association for the Promotion of Sciences and Humanities in Germany, Germany
- French Ministry of Health as part of
- Friedrich-Baur Foundation, Munich, Germany
- Frits, Georg og Marie Gluds Legat, Aarhus, Denmark
- Fukuoka Higashi Medical Center, Koga, Japan
- Fund for Scientific Research – Flanders (FWO - Vlaanderen), Brussels, Belgium
- Fundação Araucária do Paraná, Curitiba, PR, Brazil
- Fundação para a Ciência e a Tecnologia (FCT), Ministério da Ciência e Ensino Superior, Portugal
- Fundamental Research Grant, South University of Science and Technology of China, Shenzhen, P.R. China
- Funding for Excellent Departments, Qingdao University, Qingdao, P.R. China
- Fundo Estadual para a Infância e Adolescência (FIA/PR), Curitiba, PR, Brazil
- Galenus-med GmbH, Frankfurt am Main, Germany
- Galway University Foundation, Galway, Ireland
- Gänseblümchen-Voerde Foundation, Voerde, Germany
- Gazdaságfejlesztési és Innovációs Operatív Program (GINOP), Hungary
- GE Healthcare, Chigaco, IL, U.S.A.
- Genomics and Proteomics Core Laboratory, Department of Medical Research, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, R.O.C.
- German Academic Exchange Program (DAAD), New York, NY, U.S.A.
- German Federal Ministry of Education and Research (BMBF), Germany
- German Institute of Human Nutrition, Nuthetal, Germany
- Gesellschaft für KinderKrebsforschung e.V., Geltendorf, Germany
- Global Robotics Institute, Florida Hospital, Orlando, FL, U.S.A.
- Golfer's Against Cancer Grant, Kingwood, TX, U.S.A.
- Gout Research Foundation, Tokyo, Japan
- Grand Forks Human Nutrition Research Center, Grand Forks, ND, U.S.A.
- Grant-in-Aid for Clinical Cancer Research, Ministry of Health, Labor and Welfare, Tokyo, Japan
- Grant-in-Aid for Exploratory Research, Ministry of Education, Culture, Sports, Science and Technology (MEXT), Tokyo, Japan
- Grant-in-Aid for Graduate Students, Hyogo College of Medicine, Nishinomiya, Japan
- Grant-in-Aid for Scientific Research, Ministry of Health, Labor and Welfare of Japan, Tokyo, Japan
- Grants-in Aid for Cancer Research: Research on HTLV-1 Associated Diseases, Saga Prefecture, Japan
- Grants-in Aid for Cancer Research: Special Cancer Research, Ministry of Education, Science, Sports and Culture, Tokyo, Japan

- Grants-in-Aid for Scientific Research (KAKENHI), Japan  
 Society for the Promotion of Science, Tokyo, Japan  
 Gujarat Council on Science and Technology, Gujarat, India  
 Gujarat State Biotechnology Mission, Gujarat, India  
 Gunnar Nilssons Cancerstiftelse, Helsingborg, Sweden
- Hans-Sauer-Stiftung, Oberhaching, Germany  
 Harvard Medical School, Boston, MA, U.S.A.  
 Health and Welfare Data Science Center (HWDC), Taipei,  
 Taiwan, R.O.C.  
 Health Labour Sciences Research Grant, Ministry of Health  
 Labour and Welfare, Tokyo, Japan  
 Health Research Board, Dublin, Ireland  
 Heavy Ion Medical Accelerator in Chiba (HIMAC), Chiba,  
 Japan  
 Henry M. Jackson Foundation for the Advancement of  
 Military Medicine, Bethesda, MD, U.S.A.  
 Heriot Watt University (HWU), Edinburgh, Scotland,  
 U.K.  
 Higher Education Commission of Pakistan (FAM),  
 Islamabad, Pakistan  
 Higher Education Research Promotion, Bangkok, Thailand  
 Hiroshima Red Cross Hospital & Atomic Bomb Survivors  
 Hospital, Hiroshima, Japan  
 Hoffmann-La Roche Pharmaceuticals, Basel, Switzerland  
 Hokkaido University, Sapporo, Japan  
 Hospital Pharmacy, Fondazione IRCCS Policlinico San  
 Matteo, Pavia, Italy  
 Hubei Key Laboratory of Stem Cell Research, Taihe  
 Hospital, Hubei University of Medicine, Shiyan, P.R.  
 China  
 Hubei Science and Technology Foundation, Shiyan, P.R.  
 China  
 Hyogo Medical Center, Akashi, Japan  
 Hyogo Prefecture Health Promotion Association,  
 Nishinomiya, Japan
- Icahn School of Medicine at Mount Sinai, New York, NY,  
 U.S.A.  
 Ichiro Kanehara Foundation, Japan  
 Iizuka Hospital, Fukuoka, Japan  
 Imperial Life Sciences (P) Limited, Gurugram, India  
 Incubating Program for Clinical Research and Innovation,  
 Renji Hospital Affiliated to Shanghai Jiao Tong  
 University School of Medicine, Shanghai, P.R. China  
 Indian Council for Medical Research, New Delhi, India  
 Innovative Economy Operational Program, National  
 Strategic Reference Framework Program, European  
 Union, Brussels, Belgium
- Innovative Economy Operational Program, Provincial  
 Specialized Hospital, Research and Development Center,  
 Wroclaw, Poland  
 Innovative Social Policies for Inclusive and Resilient  
 Labour Markets in Europe (INSPiRE), Seventh  
 Framework Programme, European Commission,  
 Brussels, Belgium  
 Inoue Enryou Memorial Foundation, Toyo University,  
 Tokyo, Japan  
 Institut Curie, Paris, France  
 Institut National de la Santé et de la Recherche Médicale,  
 France  
 Institute of Biomathematics, Faculty of Medicine,  
 Mannheim, Germany  
 Institute of Bioorganic Chemistry Core Facility (CKP  
 IBCH), Moscow, Russian Federation  
 Institute of Dentistry, University of Turku, Turku, Finland  
 Institute of Health Biosciences, University of Tokushima,  
 Tokushima, Japan  
 Institute of Lighting Technics, Technical University Berlin,  
 Berlin, Germany  
 Instituto de Medicina Molecular, Faculdade de Medicina de  
 Lisboa, Lisbon, Portugal  
 Internal Grant Agency (IGA), Ministry of Health, Prague,  
 Czech Republic  
 International Comparisons of Product Supply Chains in the  
 Agro-food Sectors (COMPETE), Seventh Framework  
 Programme, European Commission, Brussels, Belgium  
 IPSEN Pharma GmbH, Ettlingen, Germany  
 Ireland Alumni Student Research Programme, Royal  
 College of Surgeons, Dublin, Ireland  
 Irish Cancer Society, Dublin, Ireland  
 Italian Association for Cancer Research (Associazione  
 Italiana per la Ricerca sul Cancro, AIRC), Italy  
 Ithoh-Chubei Foundation, Japan
- James and Esther King Florida Biomedical Research  
 Program, Florida Department of Health, Tallahassee, FL,  
 U.S.A.  
 János Bolyai Research Scholarship, Hungarian Academy of  
 Sciences, Budapest, Hungary  
 Japan Agency for Medical Research and Development  
 (AMED), Tokyo, Japan  
 Japan Foundation for Applied Enzymology (JFAE), Osaka,  
 Japan  
 Japan Science and Technology Agency (JST), Kawaguchi,  
 Japan  
 Japan Society for the Promotion of Science (JSPS), Tokyo,  
 Japan

- Jeju National University Hospital, Jeju, Republic of Korea  
 John P. Murtha Cancer Center, Johnstown, PA, U.S.A.  
 Johns Hopkins University, Baltimore, MD, U.S.A.  
 Jules Bordet Institute, Free University of Brussels, Brussels, Belgium
- K2R2R Award, Intermountain Foundation, Primary Children's Hospital, Salt Lake City, UT, U.S.A.  
 Kakahara Science and Technology Foundation, Fukuoka, Japan  
 Kanagawa Health Foundation, Japan  
 Kanagawa Prefectural Hospitals Cancer Fund, Japan  
 Kanazawa Medical Research Foundation, Kanazawa, Japan  
 Kaohsiung Medical University Hospital, Kaohsiung City, Taiwan, R.O.C.  
 Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan, R.O.C.  
 Karen A. Tolstrups Fund, Denmark  
 Karl-Olga-Krankenhaus GmbH, Stuttgart, Germany  
 Karolinska Institutet, Stockholm, Sweden  
 KfH Nephrological Center Moabit, Berlin, Germany  
 Khon Kaen University, Khon Kaen, Thailand  
 King Abdulaziz City for Science and Technology (KACST), Riyadh, Saudi Arabia  
 King Gustav V Jubilee Fund, Stockholm, Sweden  
 Klinikum Stuttgart, Stuttgart, Germany  
 Kochi Medical Center, Kochi, India  
 Kochi University Hospital, Kochi, India  
 Korea Health Industry Development Institute (KHIDI), Ministry of Health & Welfare, Seoul, Republic of Korea  
 Korea Health Technology R&D Project, Ministry of Health & Welfare, Seoul, Republic of Korea  
 Korea Institute of Radiological and Medical Sciences (KIRAMS), Ministry of Science, ICT and Future Planning, Gwacheon, Republic of Korea  
 Korean Health Technology R&D Project, Ministry of Health & Welfare, Seoul, Republic of Korea  
 Kuopio University Hospital, Kuopio, Finland  
 KUREHA Co. Ltd., Tokyo, Japan  
 Kyoto University, Kyoto, Japan  
 Kyowa Hakko Kirin Co. Ltd., Tokyo, Japan  
 Kyushu Central Hospital, Fukuoka, Japan  
 Kyushu University Hospital, Fukuoka, Japan  
 Kyushu University, Fukuoka, Japan
- Laboratory Animal Facilities, Jikei University School of Medicine, Tokyo, Japan
- Laboratory for Process Engineering, Environment, Biotechnology and Energy (LEPABE), Faculty of Engineering of Porto (FEUP), Porto, Portugal  
 Lancaster – Coty International Inc., London, U.K.  
 Laval University Cancer Research Center, Laval, QC, Canada  
 Lega Italiana Per La Lotta Contro i Tumori (LILT), Naples, Italy  
 Les Amis de Bordet, Brussels, Belgium  
 Life Sciences Research Network Wales, Wales, U.K.  
 Lifelong Learning Programme (LLP) Erasmus Programme, European Union  
 London Regional Cancer Program, London, U.K.  
 Louis Stokes Alliances for Minority Participation (LSAMP) National Science Foundation Grant, Arlington, VA, U.S.A.  
 Ludwig-Maximilians-University (LMU), Munich, Germany
- M.D. Anderson Cancer Center, Houston, TX, U.S.A.  
 MacArthur Foundation, Chicago, IL, U.S.A.  
 Magnetic Resonance Imaging Center, Hamburg, Germany  
 Mama Mare Breast Cancer Foundation, Easton, PA, U.S.A.  
 Manchester Metropolitan University, Manchester, U.K.  
 Marienhospital Stuttgart, Stuttgart, Germany  
 Masaryk Memorial Cancer Institute, Brno, Czech Republic  
 Max og Inger Wørzners Mindelegat, Denmark  
 Media Service, Minneapolis Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN, U.S.A.  
 Medical Prognosis Institute, Hørsholm, Denmark  
 Medical Research Core Facilities Center, Office of Research & Development, China medical University, Taichung, Taiwan, R.O.C.  
 Medical School, University of Ioannina, Ioannina, Greece  
 Medical University of Gdańsk, Gdańsk, Poland  
 Medical-Engineering Joint Fund, Shanghai Jiao Tong University, Minhang Qu, P.R. China  
 Medi-Kelsey Ltd, Ashbourne, U.K.  
 Meikai University School of Dentistry, Urayasu, Japan  
 Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, NY, U.S.A.  
 Ministry of Agriculture, Forestry and Fisheries, Tokyo, Japan  
 Ministry of Economics and Science of the Saarland, Germany  
 Ministry of Education Youth and Sports, Prague, Czech Republic  
 Ministry of Education, Culture, Sports, Science and Technology (MEXT), Tokyo, Japan

- Ministry of Education, Science and Technology, Seoul, Republic of Korea
- Ministry of Health & Welfare, Sejong City, Republic of Korea
- Ministry of Health and Welfare, Executive Yuan, Taipei, Taiwan, R.O.C.
- Ministry of Health, Labor and Welfare, Tokyo, Japan
- Ministry of Health, Prague, Czech Republic
- Ministry of Science and Higher Education, Warsaw, Poland
- Ministry of Science and Technology, Taipei, Taiwan, R.O.C.
- Ministry of Science and Technology, Taipei, Taiwan, R.O.C.
- Ministry of Science, Education and Sports (MZOS), Zagreb, Republic of Croatia
- Ministry of Science, ICT & Future Planning (MSIP), Gwacheon, Republic of Korea
- Molecular-Genetics Laboratory, Department of Hematology and Oncology, Faculty Hospital Pilsen, Pilsen, Czech Republic
- Mrs. Berta Kamprad Foundation, Sweden
- Münchener Medizinische Wochenschrift (MMW), Germany
- MVZ Labor Limbach Berlin GbR, Berlin, Germany
- Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan
- Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
- Nakatomi Foundation, Tokyo, Japan
- Nakatsu Municipal Hospital, Nakatsu, Japan
- Nambour Skin Cancer Study, Nambour, QLD, Australia
- Nanotechnology Innovation Center Kansas State (NICKS), Manhattan, KS, U.S.A.
- National Agency for Scientific Research (NASR), Tripoli, Libya
- National Cancer Center Research and Development Fund, Japan
- National Cancer Database (NCDB), Chicago, IL, U.S.A.
- National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
- National Center for Research Resources, NIH, Bethesda, MD, U.S.A.
- National Institute for General Medical Sciences (NIGMS), Bethesda, MD, U.S.A.
- National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, MD, U.S.A.
- National Institute of Minority Health and Health Disparities (NIMHD), NIH, Bethesda, MD, U.S.A.
- National Institute of Radiological Sciences (NIRS), Chiba, Japan
- National Institute on Aging, Bethesda, MD, U.S.A.
- National Institutes of Health, Department of Health and Human Services, Bethesda, MD, U.S.A.
- National Kyushu Cancer Center, Japan
- National Natural Science Foundation of China, Guangdong, P.R. China
- National Natural Science Foundation of Zhejiang Province, Zhejiang, P.R. China
- National Plan for Science, Technology and Innovation (MAARIFAH), Riyadh, Kingdom of Saudi Arabia
- National R&D Program, Korea Institute of Radiological and Medical Sciences, Ministry of Science, ICT & Future Planning (MSIP), Gwacheon, Republic of Korea
- National Research Council, Khartoum, Sudan
- National Research Foundation of Korea (NRF), Ministry of Education, Science and Technology, Seoul, Republic of Korea
- National Research Network Wales, Wales, U.K.
- National Research Program in Biomedicine, Latvia
- National Science Centre (NCN), Krakow, Poland
- National Science Council of Taiwan, Taipei, Taiwan, R.O.C.
- National Science Foundation (NSF), Arlington, VA, U.S.A.
- National Science Fund of Bulgaria, Sofia, Bulgaria
- National Sustainability Program I (NPU I), Ministry of Education Youth and Sports, Prague, Czech Republic
- Natural Science Foundation of Shandong Province, Shandong, P.R. China
- Natural Science Foundation, Jiangsu Science and Technology Department, Jiangsu, P.R. China
- Neurofibromatosis Outpatient Center, Department of Neurology, Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg, Germany
- NHO Kochi Hospital, Kochi, Japan
- NHS Endowment, National Health Service, London, U.K.
- NIH Intramural Research Program, Bethesda, MD, U.S.A.
- Nikon Instruments, Minneapolis, MN, U.S.A.
- Nine Fields of Occupational Injuries and Illnesses , Ministry of Health, Labour, and Welfare, Tokyo, Japan
- Nippon Suisan Kaisha, Ltd., Tokyo, Japan
- Northumbria University (NNU), Newcastle upon Tyne, U.K.
- Norwegian Institute of Public Health (NIPH), Oslo, Norway
- Norwegian Radium Hospital Research Foundation, Oslo, Norway
- Novartis Pharmaceuticals Corporation, New York, NY, U.S.A.

- Odense University Hospital, Odense, Denmark  
 Office of the Higher Education Commission, National  
 Research University Project of Thailand, Thailand  
 Oita Cancer Research Foundation, Oita, Japan  
 Oita Medical Center, Oita, Japan  
 Oita Prefectural Hospital, Oita, Japan  
 Oita Red Cross Hospital, Oita, Japan  
 Oncological Clinical Research Program, Minister of Health  
 and Solidarity, Paris, France  
 Onyx Pharmaceuticals, Inc., Whippany, NJ, U.S.A.  
 Országos Tudományos Kutatási Alapprogramok (OTKA),  
 Budapest, Hungary  
 Osaka City University Graduate School of Medicine,  
 Osaka, Japan  
 Oslo University Hospital, Oslo, Norway
- Palacký University, Olomouc, Czech Republic  
 Pathology Department, Santo António Hospital, Porto,  
 Portugal  
 Pathology Service, Saint-Sacrement Hospital, Quebec City,  
 QC, Canada  
 Pathology Translational Research Laboratory, NCI-  
 designated Norris Cotton Cancer Center, Lebanon, NH,  
 U.S.A.  
 Pathology Translational Research Laboratory, Norris  
 Cotton Cancer Center, Lebanon, NH, U.S.A.  
 Plains Area, Agricultural Research Service(ARS), U.S.  
 Department of Agriculture (USDA), Washington, DC,  
 U.S.A.  
 Positive Bioscience, Mumbai, India  
 Practical Research for Innovative Cancer Control, Japan  
 Agency For Medical Research and Development  
 (AMED), Tokyo, Japan  
 Preclinical Research Platform (PFEP), Villejuif, France  
 Premas Life Science, Delhi, India  
 Princess Margaret Cancer Foundation, Toronto, ON, Canada  
 Priority Research Fund, Osaka City University, Osaka,  
 Japan  
 Program to Support Young Scientists, Bulgarian Academy  
 of Science, Sofia, Bulgaria  
 Programa Operacional Competitividade e  
 Internacionalização (POCI), Lisbon, Portugal  
 Project “Terapie Innovative per il Glioblastoma”, IRCCS  
 AOU San Martino - IST, Genoa, Italy  
 Publication Clinic, Faculty of Pharmacy, Khon Kaen  
 University, Khon Kaen, Thailand
- Quadro de Referência Estratégica Nacional (QREN),  
 Portugal
- Radiation Biobank, Korea Institute of Radiological and  
 Medical Sciences (KIRAMS), Seoul, Republic of Korea  
 Radiosensitivity of Individuals and Susceptibility to Cancer  
 induced by Ionizing Radiations (RiscRad), Euratom -  
 European Commission  
 Radiumstationens Forskningsfond, Aarhus, Denmark  
 Ratchadaphiseksomphot Endowment Fund, Chulalongkorn  
 University , Thailand  
 Research and Development Center, Provincial Specialized  
 Hospital, Wroclaw, Poland  
 Research Centers in Minority Institutions (RCMI) Center  
 for Environmental Health, Jackson State University  
 (JSU), Jackson, MS, U.S.A.  
 Research Council of Lithuania, Vilnius, Lithuania  
 Research Council of Norway, Lysaker, Norway  
 Research Potential of Convergence Regions (REGPOT),  
 Seventh Framework Programme, European Commission,  
 Brussels, Belgium  
 Research Service, Minneapolis Veterans Affairs Medical  
 Center, Minneapolis, MN, U.S.A.  
 Research Support Center, Division of Clinical Science,  
 Dokkyo Medical University, Tochigi, Japan  
 Réseau de Recherche sur le Cancer, Fonds de la Recherche  
 en Santé du Québec (FRQS), Montréal, QC, Canada  
 Respiratory Clinic, Turku University Hospital, Turku,  
 Finland  
 rgb Onkologisches Management GmbH, Sarstedt, Germany  
 RIKEN Advanced Institute for Computational Science,  
 Wako, Japan  
 Robert-Bosch-Hospital, Stuttgart, Germany  
 Roche Diagnostics GmbH, Penzberg, Germany  
 Roche Pharma AG, Grenzach-Wyhlen, Germany  
 Roche Products Pvt. Ltd., Mumbai, India  
 Rouen University Hospital, Rouen, France  
 Russian Science Foundation (RSF), Moscow, Russian  
 Federation
- Sabinsa Corporation – NJ, East Windsor, NJ, U.S.A.  
 Saga University, Saga, Japan  
 Saiseikai Fukuoka General Hospital, Fukuoka, Japan  
 Saiseikai Karatsu Hospital, Karatsu, Japan  
 Saiseikai Yahata Hospital, Yahata, Japan  
 Sapienza Ateneo, Rome, Italy  
 Sbarro Health Research Organization (SHRO), Pennsylvania  
 Department of Health, Philadelphia, PA, U.S.A.  
 SBI Pharmaceuticals Co., LTD., Tokyo, Japan  
 Scare Crow Inc., Tokyo, Japan  
 School of Medicine and Public Health, University of  
 Wisconsin, Madison, WI, U.S.A.

- School of Medicine, Ajou University, Suwon, Republic of Korea
- Schulich School of Medicine and Dentistry, London, ON, Canada
- Science and Technology Unit, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia
- Scientific Grant Agency, Ministry of Education, Science, Research and Sport, Bratislava, Slovak Republic
- Screening Core Facility, National Centre for Biomedical Engineering Science (NCBES), Galway, Ireland
- Secretaria da Ciência, Tecnologia e Ensino Superior (SETI), Curitiba, PR, Brazil
- Secretaria da Família e Desenvolvimento Social (SEDS), Curitiba, PR, Brazil
- Seoul National University Hospital (SNUH) Research Fund, Seoul, Republic of Korea
- Shandong Province Young and Middle-aged Scientists Research Award of China, P.R. China
- Shanghai Fund for Young Physician Development, Shanghai, P.R. China
- Shanghai Pujiang Program, Shanghai, P.R. China
- Shared Resource Support Grant, University of Colorado Cancer Center, Denver, CO, U.S.A.
- Shenzhen Municipal Research Funds, Shenzhen, Hong Kong, P.R. China
- Shin-Nakama Hospital, Nakama, Japan
- Shizuoka Cancer Center Hospital, Shizuoka, Japan
- Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
- Sint Antonius Hospital, Nieuwegein, the Netherlands
- Slovak Research and Development Agency (SRDA), Bratislava, Slovak Republic
- Smoking Research Foundation (SRF), Tokyo, Japan
- Social Insurance Nakabaru Hospital, Kasuya, Japan
- Sonja Wasowicz Stiftung zur Förderung der Medizinischen Forschung, Essen, Germany
- Soonchunhyang University Research Fund, Asan, Republic of Korea
- South-Eastern Norway Regional Health Authority, Hamar, Norway
- Specialization Project Research Grant, Pusan National University, Busan, Republic of Korea
- Specific Health Problem in Greater Mekong Sub-region (SHeP-GMS), Health Cluster, National Research University Project of Thailand, Thailand's Office of the Higher Education Commission (OHEC), Bangkok, Thailand
- Spogaards Family Fund, Denmark
- Stanford University, Stanford, CA, U.S.A.
- Stanley Tassis Fund, Toronto, ON, Canada
- Startup Funds, Ministry of Education (MOE), Beijing, P.R. China
- Steel Memorial Yahata Hospital, Kitakyushu, Japan
- Stockholm Cancer Society, Stockholm, Sweden
- Stockholm City Council, Stockholm, Sweden
- Study of the Health Effects of Radiation, Ministry of the Environment, Tokyo, Japan
- Supercomputer System, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
- Supported Programs for the Strategic Research Foundations at Private Universities, MEXT, Japan
- Swedish Breast Cancer Association (Bröstcancerföreningarnas Riksorganisation, BRO), Stockholm, Sweden
- Swedish Cancer Foundation, Stockholm, Sweden
- Swedish Cancer Society, Stockholm, Sweden
- Szeged Foundation for Cancer Research (Szegedi Rákkutatásért Alapítvány), Szeged, Hungary
- Tagawa Municipal Hospital, Tagawa, Japan
- Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
- Taichung Tzu Chi Hospital, Taichung, Taiwan, R.O.C.
- Taiho Pharmaceutical Co. Ltd., Tokyo, Japan
- Taiwan Academia Sinica Thematic Project, Taiwan, R.O.C.
- Takeda Chemical Industries
- Takeda Science Foundation, Japan
- Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan City, Taiwan R.O.C.
- Társadalmi Megújulás Operatív Program (TÁMOP), Hungary
- Thailand Research Fund, Bangkok, Thailand
- Thelma Mäkikyrö Foundation, Sweden
- Thuréus foundation, Uppsala, Sweden
- Tissue Bank, China Medical University, Taichung, Taiwan R.O.C.
- Translational Research Informatics (TRI) Center, Kobe, Japan
- TRF Senior Research Grant, Thailand Research Fund, Bangkok, Thailand
- TriStar Technology Group, Rockville, MD, U.S.A.
- Tsukuba University, Ibaraki, Japan
- Turku University, Turku, Finland
- Uehara Memorial Foundation, Tokyo, Japan
- Umea University, Umea, Sweden
- Undergraduate Research Opportunities Program (UROP), Boston University, Boston, MA, U.S.A.

Unit of Molecular Therapies, Department of Experimental  
Oncology and Molecular Medicine, Fondazione IRCCS  
Istituto Nazionale dei Tumori, Milan, Italy  
Unité de Nutrition Humaine UMR 1019 INRA-UdA-Equipe  
ECREIN, St Genès Champanelle, France  
United States Department of Defense, The Pentagon,  
Arlington, VA, U.S.A.  
University of Aberdeen, Aberdeen, Scotland, U.K.  
University of Aveiro, Aveiro, Portugal  
University of Brescia, Brescia, Italy  
University of Helsinki, Helsinki, Finland  
University of Maryland., College Park, MD, U.S.A.  
University of Michigan, Ann Arbor, MI, U.S.A.  
University of Minnesota, Minneapolis, MN, U.S.A.  
University of Pécs, Pécs, Hungary  
University of Salford, Salford, U.K.  
University of South Florida (USF) Research Foundation,  
Tampa, FL, U.S.A.  
University of Southern Denmark, Odense, Denmark  
University of Tübingen, Tübingen, Germany  
University of Wisconsin Carbone Cancer Center, Madison,  
WI, U.S.A.  
University of Wisconsin, Madison, WI, U.S.A.  
UV-Technik, Hanau, Germany

Vanderbilt University School of Medicine, Nashville, TN,  
U.S.A.  
Vasterbotten County Council (ALF), Umea, Sweden  
Victor Babes University of Medicine and Pharmacy,  
Timisoara, Romania  
  
Wake Forest University, Winston-Salem, NC, U.S.A.  
Walter Reed National Military Medical Center, Bethesda,  
MD, U.S.A.  
Wellcome Trust, London, U.K.  
West Virginia IDEa Network of Biomedical Research  
Excellence, West Virginia, U.S.A.  
World Cancer Research Fund International, London, U.K.  
Wroclaw Medical University, Wroclaw, Poland  
Wrovasc – Integrated Cardiovascular Centre, Wroclaw,  
Poland  
  
Yantai Science and Technology Program, Yantai University,  
Yantai, P.R. China  
Yantai Yuhuangding Hospital Initiative Foundation for  
Young, Yantai University, Yantai, P.R. China  
Yen Tjing Ling Medical Foundation, Taiwan, R.O.C.



## Instructions for Authors 2017

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.)). New York, Plenum Publ Corp., pp 113-136, 1973.

***Nomenclature and Abbreviations.*** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

***Clinical Trials.*** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

***Ethical Policies and Standards.*** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

***Submission of Manuscripts.*** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html>. In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org)

***Galley Proofs.*** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

### ***Specific information and additional instructions for Authors***

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions for authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

**Copyright© 2017** - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

## Reviews